Exelixis Entered into a License Agreement with Ajinomoto Co. to Discover and Develop Novel Antibody-Drug Conjugates for Cancer
Shots:
- Ajinomoto Co. is eligible to receive development, regulatory and commercial milestones along with royalties on commercial sales. Exelixis will get the rights to use AJICAP technology to advance multiple ADCs that have the potential to be more effective and less toxic compared to currently available options
- The collaboration will combine Exelixis' Abs and payloads with Ajinomoto Co.'s AJICAP site-specific bioconjugation and linker technologies to develop Exelixis' ADC programs for cancer patients
- Exelixis’ goal is to advance the discovery, development & commercialization of new therapies for difficult-to-treat cancers
Ref: PRNewswire | Image: Exelixis
Related News:- Merck Signs a Research Collaboration and Commercial License Agreement with Mersana for Novel Antibody-Drug Conjugates
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
